Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -22.5%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $151M | $219M | $284M | $44M | $199M | $104M | $1.1B | — | — | — |
| Enterprise Value | $-16105342 | $134M | $209M | $271M | $30M | $185M | $103M | $1.0B | — | — | — |
| P/E Ratio → | -0.31 | — | — | — | — | — | — | 683.50 | — | — | — |
| P/S Ratio | 0.58 | 86.83 | 113.35 | 144.21 | 16.78 | 41.57 | 20.12 | 150.04 | — | — | — |
| P/B Ratio | 0.07 | 9.79 | 15.69 | 19.35 | 2.66 | 12.44 | 11.05 | 94.71 | — | — | — |
| P/FCF | — | — | — | — | 212.20 | — | 196.85 | — | — | — | — |
| P/OCF | — | — | — | — | 162.77 | — | 111.17 | 4398.36 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 77.00 | 108.46 | 137.30 | 11.60 | 38.79 | 20.01 | 148.77 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | 22.37 | 534.85 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 580.63 | — | — | — |
| EV / FCF | — | — | — | — | 146.71 | — | 195.79 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 21.1% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% | 48.5% | 47.4% | 21.4% |
| Operating Margin | -154.0% | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% | 83.0% | 25.2% | 23.3% | 32.8% | 5.6% |
| Net Profit Margin | -189.8% | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% | -199.3% | 22.0% | 16.9% | 24.3% | 3.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -22.5% | -22.5% | -21.7% | -38.1% | -35.4% | -21.7% | -100.3% | 21.4% | 46.2% | 91.3% | 19.1% |
| ROA | -14.8% | -14.8% | -11.8% | -18.8% | -16.8% | -9.8% | -52.5% | 12.3% | 18.1% | 20.2% | 2.2% |
| ROIC | -142.0% | -142.0% | -67.5% | -208.9% | -138.6% | -28.6% | 58.0% | 49.6% | 47.1% | 72.8% | 13.0% |
| ROCE | -17.9% | -17.9% | -17.2% | -35.6% | -32.0% | -17.3% | 41.6% | 24.5% | 63.5% | 123.5% | 28.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.19 | 0.26 | 0.12 | 0.00 | 0.72 | 0.02 | 0.12 | 0.16 | 0.65 |
| Debt / EBITDA | — | — | — | — | — | — | 1.46 | 0.13 | 0.22 | 0.18 | 1.61 |
| Net Debt / Equity | — | -1.11 | -0.68 | -0.93 | -0.82 | -0.83 | -0.06 | -0.80 | -0.05 | 0.13 | 0.63 |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.12 | -4.55 | -0.10 | 0.14 | 1.57 |
| Debt / FCF | — | — | — | — | -65.49 | — | -1.07 | — | -0.20 | 2.22 | 5.47 |
| Interest Coverage | -4.14 | -4.14 | -4.62 | -11.76 | -141.43 | -1.36 | 1.28 | 342.00 | 2095.34 | 39.67 | — |
Net cash position: cash ($18M) exceeds total debt ($983877)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 | 1.37 | 1.05 |
| Quick Ratio | 3.40 | 3.40 | 1.51 | 1.31 | 1.25 | 1.20 | 1.53 | 2.31 | 1.11 | 1.09 | 0.74 |
| Cash Ratio | 3.01 | 3.01 | 1.36 | 1.20 | 0.91 | 0.72 | 0.59 | 1.44 | 0.13 | 0.02 | 0.00 |
| Asset Turnover | — | 0.08 | 0.08 | 0.07 | 0.08 | 0.14 | 0.24 | 0.40 | 0.92 | 0.90 | 0.59 |
| Inventory Turnover | 1.66 | 1.66 | 1.70 | 2.91 | 1.33 | 2.25 | 2.75 | 2.38 | 2.86 | 2.52 | 1.70 |
| Days Sales Outstanding | — | 398.39 | 254.83 | 248.91 | 775.01 | 593.38 | 752.83 | 256.75 | 203.48 | 239.72 | 398.90 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 0.1% | — | — | — |
| FCF Yield | — | — | — | — | 0.5% | — | 0.5% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $403920 | $867422 | $266973 | $41591 | $28782 | $12364 | $10284 | $0 | $0 | $0 |
Unsustainable Operational Cash Burn
According to recent market data, SXTC trades at a P/S ratio of 0.56, which, while appearing cheap relative to broader healthcare peers, reflects the market's skepticism regarding the company's ability to reverse its persistent revenue contraction and achieve a sustainable path toward positive earnings.
The current valuation appears to be driven almost entirely by the company's cash-heavy balance sheet rather than its underlying pharmaceutical operations. Investors should monitor whether the discount to book value, currently at a P/B of 0.06, indicates a terminal value assessment by the market or a potential mispricing of the firm's remaining tangible assets.
Based on reported figures, the company's ROIC has frequently trended into negative territory, reaching -32.5% in recent quarters, which highlights a fundamental inability to generate returns on invested capital that exceed the cost of maintaining its specialized TCM processing infrastructure.
The erratic nature of these returns suggests that the company is failing to compound value, with efficiency metrics hampered by high fixed costs and a lack of scale. This trend warrants further investigation into whether the firm's capital allocation strategy is fundamentally flawed or if the current market environment for TCMP products is structurally prohibitive to profitability.
As reported in financial statements, the company's cash conversion cycle has ballooned to over 1,100 days in recent periods, a figure that significantly lags industry norms and underscores the extreme difficulty the firm faces in converting its inventory of medicinal herbs into realized cash flow.
The exceptionally high DSO and DIO metrics suggest that the company lacks leverage over its hospital customers and is struggling with inventory turnover. This inefficiency appears to be a structural drag on liquidity, as capital remains trapped in slow-moving inventory and uncollected receivables for extended periods.
While the company maintains a current ratio of 3.54, as evidenced by recent balance sheet data, this liquidity position is misleading because it is primarily supported by a cash reserve that is being steadily depleted to fund ongoing operating losses rather than productive growth initiatives.
The quick ratio of 3.40 confirms that the firm has sufficient short-term assets to cover immediate liabilities, yet this provides only a temporary shield against the underlying cash burn. Investors should monitor the rate of cash depletion, as the current trajectory suggests that the company's liquidity cushion may be insufficient to support long-term operations without a significant pivot in business strategy.
The Price-to-Book ratio is the most commonly misapplied metric for SXTC, as it obscures the reality that the company's book value is largely composed of cash and potentially impaired inventory rather than productive, revenue-generating assets that could support future growth or shareholder returns.
Relying on P/B in this context is dangerous because it ignores the high probability of future asset write-downs and the ongoing erosion of equity through persistent net losses. Analysts should instead focus on the cash burn rate and the sustainability of the operating margin to gauge the true economic health of the business.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SXTC stock.
China SXT Pharmaceuticals, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
China SXT Pharmaceuticals, Inc.'s return on equity (ROE) is -22.5%. The historical average is -6.2%.
Based on historical data, China SXT Pharmaceuticals, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
China SXT Pharmaceuticals, Inc. has 21.1% gross margin and -154.0% operating margin.